Consun Pharmaceutical Group (HKSE:01681) Debt-to-Revenue : 0.17 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Consun Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$555 Mil. Consun Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$4 Mil. Consun Pharmaceutical Group's annualized Revenue for the quarter that ended in Dec. 2023 was HK$3,217 Mil. Consun Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.17.

Consun Pharmaceutical Group Debt-to-Revenue Historical Data

The historical data trend for Consun Pharmaceutical Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Debt-to-Revenue Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.32

0.31

0.30

0.20

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.26	0.24	0.17	0.24	0.17

Competitive Comparison of Consun Pharmaceutical Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Debt-to-Revenue falls into.

Consun Pharmaceutical Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Consun Pharmaceutical Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(555.242	+	4.264)	/	2833.013
	=	0.20

Consun Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(555.242	+	4.264)	/	3216.664
	=	0.17

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Consun Pharmaceutical Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Executives

An Yubao	2101 Beneficial owner
Li Qian	2101 Beneficial owner
Central Success Developments Limited	2101 Beneficial owner
Aali Resources Limited	2201 Interest of corporation controlled by you
Bos Trustee Limited	2301 Trustee
Zhang Lihua	2202 Interest of your spouse
An Meng	2101 Beneficial owner
Double Grace International Limited	2101 Beneficial owner
Bos Trustee Limited As Trustee	2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines